Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
kaletra | New Drug Application | 2023-07-06 |
lopinavir and ritonavir | ANDA | 2023-10-20 |
lopinavir-ritonavir | ANDA | 2020-11-18 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 24 | 64 | 81 | 71 | 61 | 283 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 6 | 12 | 21 | 19 | 19 | 73 |
Covid-19 | D000086382 | — | U07.1 | 1 | 22 | 27 | 5 | 20 | 65 |
Hiv | D006678 | — | O98.7 | 10 | 9 | 10 | 20 | 15 | 60 |
Infections | D007239 | EFO_0000544 | — | 4 | 9 | 15 | 11 | 10 | 48 |
Immunologic deficiency syndromes | D007153 | — | D84.9 | 2 | 2 | 10 | 4 | 9 | 25 |
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 8 | 7 | 2 | 9 | 23 |
Communicable diseases | D003141 | — | — | — | 5 | 5 | 7 | 4 | 20 |
Pneumonia | D011014 | EFO_0003106 | J18 | — | 3 | 3 | 2 | 9 | 15 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 3 | 6 | — | 4 | 1 | 14 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis c | D006526 | — | B19.2 | 2 | 2 | 2 | — | 3 | 9 |
Hepatitis | D006505 | — | K75.9 | — | 2 | 2 | — | 3 | 7 |
Virus diseases | D014777 | — | B34 | — | 1 | 3 | — | 3 | 7 |
Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | 1 | 3 | — | 2 | 5 |
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 1 | 1 | — | 3 | 5 |
Hepatitis a | D006506 | EFO_0007305 | B15 | — | 1 | 1 | — | 2 | 4 |
Syndrome | D013577 | — | — | 1 | 1 | 1 | — | 2 | 4 |
Hiv-2 | D015498 | — | — | — | — | 1 | — | — | 1 |
Breast feeding | D001942 | — | — | — | — | 1 | — | — | 1 |
Respiratory tract infections | D012141 | — | J06.9 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | — | — | 3 | 4 |
Coronavirus | D017934 | — | — | — | 1 | — | — | 2 | 3 |
Hepatitis b | D006509 | — | — | — | 1 | — | — | 1 | 2 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | 1 | 2 |
Fibrosis | D005355 | — | — | — | 1 | — | — | 1 | 2 |
Disease progression | D018450 | — | — | 1 | 1 | — | — | — | 2 |
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 2 |
Renal insufficiency | D051437 | — | N19 | — | 1 | — | — | — | 1 |
Viremia | D014766 | — | B34.9 | — | 1 | — | — | — | 1 |
Disease | D004194 | EFO_0000408 | R69 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Insulin resistance | D007333 | EFO_0002614 | E88.819 | 2 | — | — | — | 1 | 3 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | 1 | 2 |
Long qt syndrome | D008133 | HP_0001657 | I45.81 | 1 | — | — | — | — | 1 |
Pharmacological phenomena | D000069437 | — | — | 1 | — | — | — | — | 1 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Hypertriglyceridemia | D015228 | EFO_0004211 | — | 1 | — | — | — | — | 1 |
Carcinoma in situ | D002278 | — | D09.9 | 1 | — | — | — | — | 1 |
Squamous intraepithelial lesions of the cervix | D065310 | — | — | 1 | — | — | — | — | 1 |
Therapeutics | D013812 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 2 | 2 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | — | — | 1 | 1 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 1 | 1 |
Wasting syndrome | D019282 | — | — | — | — | — | — | 1 | 1 |
Cachexia | D002100 | — | R64 | — | — | — | — | 1 | 1 |
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
Drug common name | Lopinavir |
INN | lopinavir |
Description | Lopinavir is a dicarboxylic acid diamide that is amphetamine is substituted on nitrogen by a (2,6-dimethylphenoxy)acetyl group and on the carbon alpha- to nitrogen by a (1S,3S)-1-hydroxy-3-{[(2S)-3-methyl-2-(2-oxotetrahydropyrimidin-1-yl)butanoyl]amino}-4-phenylbutyl group. An antiretroviral of the protease inhibitor class, it is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir. It has a role as an antiviral drug, a HIV protease inhibitor and an anticoronaviral agent. It is a member of amphetamines and a dicarboxylic acid diamide. |
Classification | Small molecule |
Drug class | antivirals: HIV protease inhibitors (saquinavir type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O |
PDB | — |
CAS-ID | 192725-17-0 |
RxCUI | — |
ChEMBL ID | CHEMBL729 |
ChEBI ID | 31781 |
PubChem CID | 92727 |
DrugBank | DB01601 |
UNII ID | 2494G1JF75 (ChemIDplus, GSRS) |